URGENT:COVID prophylaxis | Vitamin D | Latest research | NIH | CDC | Worldometer
Information about Repaglinide
Repaglinide is a benzoic acid derivative that stimulates insulin secretion from the pancreas and is used in the therapy of type 2 diabetes.
Liver safety of Repaglinide
Repaglinide has been linked to rare instances of clinically apparent acute liver injury.
Mechanism of action of Repaglinide
Repaglinide (re pag' li nide) is an insulin secretagogue that is similar in action but different in structure from the sulfonylureas. It is a benzoid acid derivative that, like the sulfonylureas, stimulates insulin secretion by blocking ATP sensitive potassium channels in pancreatic beta-cells, causing cell membrane depolarization which results in calcium influx and insulin secretion. Repaglinide has been shown to reduce the postprandial increase in glucose in patients with type 2 diabetes and improve glycemic control. Repaglinide
FDA approval information for Repaglinide
Repaglinide was approved for use in the United States in 1997. The current indications are for management of type 2 diabetes used in combination with diet and exercise, with or without other oral hypoglycemic agents.
Brand name for Repaglinide
Repaglinide is available generically and under the brand name Prandin in tablets of 0.5, 1 and 2 mg.
Dosage and administration for Repaglinide
The typical initial dose in adults is 0.5 mg three times daily before meals, with a gradual increase to a maximum of 16 mg daily.
Side effects of Repaglinide
- Alpha-Glucosidase Inhibitors
- Incretin-Based Drugs
- Metiglinide Analogues
- Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitors